
    
      Gemcitabine plus nab-Paclitaxel is one of the standard chemotherapy for metastatic pancreatic
      adenocarcinoma. Gemcitabine plus nab-Paclitaxel realize the favorable anti-tumor effect and
      tolerable toxicity. Gemcitabine plus nab-Paclitaxel is a promising regimen for concurrent
      chemoradiotherapy, but the investigators need to know the safety in the case of the
      concurrent chemoradiotherapy.
    
  